Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
5.95
-0.10 (-1.65%)
At close: Aug 29, 2025, 4:00 PM
5.85
-0.10 (-1.68%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Tharimmune Employees
As of December 31, 2024, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,004,420
Market Cap
27.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
THAR News
- 9 days ago - Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Accesswire
- 16 days ago - Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - Accesswire
- 24 days ago - Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors - Accesswire
- 25 days ago - Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery - Accesswire
- 5 weeks ago - Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants - Accesswire
- 2 months ago - Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - Accesswire
- 4 months ago - Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Accesswire
- 4 months ago - Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Accesswire